期刊文献+
共找到4篇文章
< 1 >
每页显示 20 50 100
Donor-Derived CD19-Targeted T Cell Infusion Eliminates B Cell Acute Lymphoblastic Leukemia Minimal Residual Disease with No Response to Donor Lymphocytes after Allogeneic Hematopoietic Stem Cell Transplantation 被引量:7
1
作者 yifei cheng Yuhong Chen +11 位作者 Chenhua Yan Yu Wang Xiangyu Zhao Yao Chen Wei Han Lanping Xu Xiaohui Zhang Kaiyan Liu Shasha Wang Lungji Chang Lei Xiao Xiaojun Huang 《Engineering》 SCIE EI 2019年第1期150-155,共6页
Leukemia relapse is still the leading cause of treatment failure after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for B cell acute lymphoblastic leukemia (B-ALL). Relapsed patients with BALL after ... Leukemia relapse is still the leading cause of treatment failure after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for B cell acute lymphoblastic leukemia (B-ALL). Relapsed patients with BALL after allo-HSCT have a very short median survival. Minimal residual disease (MRD) is predictive of forthcoming hematological relapse after hematopoietic stem cell transplantation (HSCT);furthermore, eliminating MRD effectively prevents relapse. Donor lymphoblastic infusion (DLI) is the main established approach to treat B-ALL with MRD after allo-HSCT. However, about one-third of patients with MRD are non-responsive to DLI and their prognosis worsens. Although donor-derived cluster of differentiation (CD)19-directed chimeric antigen receptor-modified (CAR) T cells (CART19s) can potentially cure leukemia, the efficiency and safety of infusions with these cells have not yet been investigated in patients with MRD after HSCT. Between September 2014 and February 2018, six patients each received one or more infusions of CART19s from HSCT donors. Five (83.33%) achieved MRD-negative remission, and one case was not responsive to the administration of CAR T cells. Three of the six patients are currently alive without leukemia. No patient developed acute graft-versus-host disease (aGVHD), and no patient died of cytokine release syndrome. Donor-derived CAR T cell infusions seem to be an effective and safe intervention for patients with MRD in B-ALL after allo-HSCT and for those who were not responsive to DLI. 展开更多
关键词 Donor-derived CD19-targeted T CELL INFUSION Hematopoietic stem CELL transplantation B CELL acute lymphoblastic leukemia Minimal residual disease
下载PDF
Accelerating local SGD for non-IID data using variance reduction
2
作者 Xianfeng LIANG Shuheng SHEN +4 位作者 Enhong CHEN Jinchang LIU Qi LIU yifei cheng Zhen PAN 《Frontiers of Computer Science》 SCIE EI CSCD 2023年第2期73-89,共17页
Distributed stochastic gradient descent and its variants have been widely adopted in the training of machine learning models,which apply multiple workers in parallel.Among them,local-based algorithms,including Local S... Distributed stochastic gradient descent and its variants have been widely adopted in the training of machine learning models,which apply multiple workers in parallel.Among them,local-based algorithms,including Local SGD and FedAvg,have gained much attention due to their superior properties,such as low communication cost and privacypreserving.Nevertheless,when the data distribution on workers is non-identical,local-based algorithms would encounter a significant degradation in the convergence rate.In this paper,we propose Variance Reduced Local SGD(VRL-SGD)to deal with the heterogeneous data.Without extra communication cost,VRL-SGD can reduce the gradient variance among workers caused by the heterogeneous data,and thus it prevents local-based algorithms from slow convergence rate.Moreover,we present VRL-SGD-W with an effectivewarm-up mechanism for the scenarios,where the data among workers are quite diverse.Benefiting from eliminating the impact of such heterogeneous data,we theoretically prove that VRL-SGD achieves a linear iteration speedup with lower communication complexity even if workers access non-identical datasets.We conduct experiments on three machine learning tasks.The experimental results demonstrate that VRL-SGD performs impressively better than Local SGD for the heterogeneous data and VRL-SGD-W is much robust under high data variance among workers. 展开更多
关键词 distributed optimization variance reduction local SGD federated learning non-IID data
原文传递
Bridging chimeric antigen receptor T-cell before transplantation improves prognosis of relapsed/refractory B-cell acute lymphoblastic leukemia
3
作者 Xiangyu Zhao Haotian Wu +7 位作者 yifei cheng Zhengli Xu Yuhong Chen Yingjun Chang Yu Wang Xiaohui Zhang Lanping Xu Xiaojun Huang 《Chinese Medical Journal》 SCIE CAS CSCD 2023年第16期2011-2013,共3页
To the Editor:For recipients with relapsed/refractory(R/R)B-cell acute lymphoblastic leukemia(B-ALL),allogeneic hematopoietic stem cell transplantation(allo-HSCT)often fails to provide them with a satisfactory prognos... To the Editor:For recipients with relapsed/refractory(R/R)B-cell acute lymphoblastic leukemia(B-ALL),allogeneic hematopoietic stem cell transplantation(allo-HSCT)often fails to provide them with a satisfactory prognosis.The chimeric antigen receptor T(CAR-T)cells are proven to be safe and effective for these patients.[1]But there are few published studies assessing the advantages of CAR-T compared to traditional chemotherapy as a bridging treatment followed by HSCT.Consequently,we conducted this study to confirm whether children and young adult R/R B-ALL patients with CAR-T therapy could expect a better post-HSCT prognosis,compared to R/R patients only receiving traditional chemotherapy before transplantation. 展开更多
关键词 chemotherapy LYMPHOBLASTIC PROGNOSIS
原文传递
Genetic variant in a BaP-activated super-enhancer increases prostate cancer risk by promoting AhR-mediated FAM227A expression
4
作者 Lulu Fan Hao Wang +7 位作者 Shuai Ben yifei cheng Silu Chen Zhutao Ding Lingyan Zhao Shuwei Li Meilin Wang Gong cheng 《Journal of Biomedical Research》 CAS 2024年第2期149-162,I0001-I0010,共24页
Genetic variants in super-enhancers(SEs)are increasingly implicated as a disease risk-driving mechanism.Previous studies have reported an associations between benzo[a]pyrene(BaP)exposure and some malignant tumor risk.... Genetic variants in super-enhancers(SEs)are increasingly implicated as a disease risk-driving mechanism.Previous studies have reported an associations between benzo[a]pyrene(BaP)exposure and some malignant tumor risk.Currently,it is unclear whether BaP is involved in the effect of genetic variants in SEs on prostate cancer risk,nor the associated intrinsic molecular mechanisms.In the current study,by using logistic regression analysis,we found that rs5750581T>C in 22q-SE was significantly associated with prostate cancer risk(odds ratio=1.26,P=7.61×10^(-5)).We also have found that the rs6001092T>G,in a high linkage disequilibrium with rs5750581T>C(r^(2)=0.98),is located in a regulatory aryl hydrocarbon receptor(AhR)motif and may interact with the FAM227A promoter in further bioinformatics analysis.We then performed a series of functional and BaP acute exposure experiments to assess biological function of the genetic variant and the target gene.Biologically,the rs6001092-G allele strengthened the transcription factor binding affinity to AhR,thereby upregulating FAM227A,especially upon exposure to BaP,which induced the malignant phenotypes of prostate cancer.The current study highlights that AhR acts as an environmental sensor of BaP and is involved in the SE-mediated prostate cancer risk,which may provide new insights into the etiology of prostate cancer associated with the inherited SE variants under environmental carcinogen stressors. 展开更多
关键词 super-enhancer prostate cancer genetic variants AhR BaP FAM227A
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部